• Successful first sale and clinical use of new deep dermal tissue product
• Extends ReNerve's commercial product range beyond nerve repair
• Anticipates bringing nerve conduit and amniotic product ranges to US market in H2 2025

ReNerve Limited (ASX, 'ReNerve' or 'the Company'), an Australian pioneering medical device company developing innovative products for peripheral nerve injury ('PNI') repair, is pleased to announce that it has successfully completed its first sale and clinical use of its new deep dermal tissue product. ReNerve is complementing its nerve product offering in the USA market with the addition of a range of dermal and amniotic products. The initial case was a reconstructive plastic surgery repair case, aiming to repair scar tissue post breast reconstruction. The case did not require nerve repair, highlighting the benefit of the two new product lines in the ReNerve commercial product range, extending the target surgical cases for the Company with both new and existing customers. CEO Dr Julian Chick stated that the first sale of the deep dermal product range is an important milestone for the Company, although the initial sale and stocking order is not material relative to annual sales. ReNerve is progressing the commercialisation of the new deep dermal and amniotic tissue-based product ranges under a strategic partnership with Berkeley Biologics LLC announced on 2 June 2025. ReNerve is also leveraging its eCOO technology, already proven through its NervAlign® Nerve Cuff, to develop and bring to market a range of nerve conduit products. The company anticipates bringing both its nerve conduit and amniotic product ranges to market in the US in the second half of this year, which should accelerate its revenue growth and complement its nerve cuff already in the market.

ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales. The company's high-margin, scalable products are positioning it as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.96 billion in 2024 and projected to reach $6.2 billion by 2031.

ReNerve is advancing a complete suite of nerve repair solutions, including the NervAlign® Nerve Cuff, Deep Dermal tissue product, Amniotic tissue product ranges, NervAlign® Nerve Conduit Range, NervAlign® Nerve Guide Matrix, and NervAlign® Bionic Nerve. The company's innovative, ready-to-use solutions for peripheral nerve injuries are delivering measurably better outcomes for patients worldwide.